Condition: Locally Advanced Solid Tumor · Metastatic Solid Tumor · Sponsor: Nuvalent Inc.
Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or metastatic human epidermal growth factor receptor 2 (HER2) -altered non-small lung cancer (NSCLC). Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the candidate RP2D(s) of NVL-330 and to determine the RP2D of NVL-330 in participants with advanced or metastatic HER2 mutant NSCLC.
This description comes directly from the study's public registry record.
Lisa Morelli · 857-357-7000 · clinicaltrials@nuvalent.com
Always discuss trial participation with your own doctor first.
| City of Hope - Lennar | Irvine, California, United States | Recruiting |
| University of California, Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| Stanford Cancer Institute | Stanford, California, United States | Recruiting |
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | Recruiting |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview Medical Center | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Cancer Center | Detroit, Michigan, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06521554